Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Essen Biotech
University of Nebraska
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Washington University School of Medicine
Fudan University
Institut Claudius Regaud
Columbia University
Arbeitsgemeinschaft medikamentoese Tumortherapie
Sheffield Teaching Hospitals NHS Foundation Trust
University Health Network, Toronto
Dana-Farber Cancer Institute
Hospices Civils de Lyon
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cedars-Sinai Medical Center
N.N. Petrov National Medical Research Center of Oncology
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Health Network, Toronto
Cambridge University Hospitals NHS Foundation Trust
Ludwig Institute for Cancer Research
Rush University Medical Center
Imperial College London
Roswell Park Cancer Institute
University Hospital, Clermont-Ferrand
Nantes University Hospital
Brown University
University of Dundee
Hospices Civils de Lyon
Shanghai Junshi Bioscience Co., Ltd.
Loma Linda University
M.D. Anderson Cancer Center
N.N. Petrov National Medical Research Center of Oncology
CureOne
Alliance for Clinical Trials in Oncology
Stanford University
Masonic Cancer Center, University of Minnesota
Comprehensive Cancer Centers of Nevada
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
Northwestern University
The Cleveland Clinic
Indiana University
Yale University
Loma Linda University
University of Chicago